What happens after an FDA approval

When a PDUFA date ends in approval, the headline is simple. The approval itself isn't. It comes with a label that defines exactly who the drug is for, sometimes with warnings, restrictions and further studies the company must run. Those details often matter as much as the approval, and they're all public.

The approval letter and the label

The FDA's action is an approval letter to the company, together with the final labelling. The most important part of the labelling is the prescribing information, often just called "the label": the document doctors rely on. It's negotiated between the FDA and the company in the last weeks of the review, which is why companies sometimes say "labelling discussions are under way" as a PDUFA date approaches.

The sections to read first:

Indications and usage: exactly which patients the drug is approved for. This can be narrower than the trial population, for example limited to patients who've tried another treatment, or to a particular genetic subtype.
Boxed warning, if there is one: the FDA's strongest warning, printed in a box at the top of the label, for serious or life-threatening risks.
Dosage and administration: how it's given, and whether that needs a clinic, monitoring or special handling.
Contraindications and warnings: who shouldn't take it and what to monitor.
Clinical studies: the trial results the FDA agreed could be described, which can differ from the company's own presentation.

Accelerated approval comes with a condition

A drug approved under accelerated approval has its indication tied to a surrogate endpoint, and the label says so. The company must complete confirmatory trials, and the indication can be withdrawn if they fail.

From the tracker

Vera Therapeutics' atacicept was approved in July 2026 "to reduce proteinuria" in IgA nephropathy under accelerated approval (8-K). The wording of the indication is the surrogate itself, and the open question is whether lower proteinuria translates into slower kidney decline. Compare Ultragenyx's UX111, which the tracker's note records as a standard full approval (Ultragenyx page).

REMS: rules on how a drug is used

For drugs with serious risks, the FDA can require a Risk Evaluation and Mitigation Strategy (REMS), under powers Congress gave it in 2007. A REMS can be as light as a medication guide for patients, or as heavy as requiring prescribers to be certified, pharmacies to be registered, or patients to have tests before each dose. A heavy REMS can slow how quickly a drug reaches patients. The FDA publishes every current REMS in a public database.

Post-marketing requirements and commitments

Approval letters often list further studies:

Post-marketing requirements (PMRs) are mandatory. They include confirmatory trials for accelerated approvals, studies in children required under the Pediatric Research Equity Act, and safety studies the FDA can require when it has a specific concern.
Post-marketing commitments (PMCs) are studies the company agrees to run but that aren't legally required.

Both are listed in the approval letter, and the FDA tracks their progress publicly. These are the "Phase 4" studies described in clinical trial phases explained.

From approval to launch

An approved drug is not always on sale the next day:

Controlled substances need to be scheduled by the Drug Enforcement Administration before they can be sold, which adds weeks to months.
Manufacturing and distribution need to be ready at commercial scale; some companies build inventory before the decision, others don't.
Insurance coverage takes time. Payers review new drugs and set coverage rules, and specialty drugs often need prior authorisation.
Partners may hold the commercial rights. An approval announced by one company can be launched by another.

Companies usually give launch timing in the approval press release or on the next results call.

Where to read the documents

Drugs@FDA holds the approval letter and label for drugs and many biologics, and later the "action package" with the FDA's own review documents, which show what the reviewers thought of the data.
The FDA's list of novel drug approvals summarises each new molecular entity approved in the year.
The company's approval press release, usually furnished on an 8-K, links to the label and often quotes its key sections.

How approvals appear on this site

When a PDUFA date ends in approval, the row moves into the decided archive on the tracker with the date of the approval and a link to the announcement. The note records whether it came early or on the date, and anything distinctive about the indication, such as an accelerated approval or a narrower label. If the approval is a Complete Response Letter instead, that guide explains what follows.

More guides

What a PDUFA date is, and why the FDA doesn't publish themThe PDUFA target action date is the FDA's own deadline for deciding on a drug application. Here is where it comes from, how it moves, and why you only hear about it from the company.
What happens at an FDA advisory committee meetingWho sits on an FDA advisory committee, how the day runs, what the vote means and doesn't mean, and where to find the documents beforehand.
What a Complete Response Letter means, and what usually followsA Complete Response Letter is the FDA's "not yet" on a drug application. What it contains, the company's options, how resubmission clocks work, and how to read the announcement.
How to read a Phase 3 topline readoutEndpoints, p-values, effect sizes, safety tables and the phrase "met its primary endpoint": a practical guide to reading the press release a company puts out when pivotal trial results land.
Clinical trial phases explained: Phase 1 to Phase 4What each phase of clinical development is for, roughly how big the trials are, what the in-between labels like 1b, 2a and 2/3 mean, and what a readout at each stage can and can't tell you.
NDA vs BLA: the two kinds of US drug applicationWhy some products are filed as a New Drug Application and others as a Biologics License Application, who reviews each, what supplements and rolling submissions are, and why the difference matters after approval.
Fast Track, Breakthrough, Priority Review and Accelerated Approval explainedThe FDA's expedited programmes are often lumped together, but they do different things at different stages. What each one is, what it changes about the timeline, and what it doesn't promise.
How to verify a catalyst date yourself on SEC EDGARA step-by-step walkthrough of the method behind this site: finding the filing that announced a PDUFA date or readout window, reading it properly, and spotting the traps that catalyst calendars fall into.
8-K vs 6-K vs press release: where catalyst dates are disclosedWhy almost every row on this site links to an 8-K exhibit, what the 6-K is for, when a press release has no filing behind it, and how the item numbers and "furnished vs filed" affect what you're reading.
Why catalyst windows like "H2 2026" are vague, and how they narrowMost biotech catalysts don't have a date, only a window the company guided to. Why that is, what the common phrases mean, how windows tighten or slip, and how this site handles them.
Orphan drug designation explainedWhat orphan designation is, the 200,000-patient threshold, the seven years of exclusivity and other incentives it brings, and what it doesn't change about an FDA review.
How the FDA reviews cell and gene therapiesCell and gene therapies go through a different part of the FDA, with heavier manufacturing scrutiny and long follow-up. What's different about their path, and what to watch in their filings.
Glossary of FDA and biotech catalyst termsPlain-English definitions of the regulatory, clinical and SEC-filing terms used across the tracker and the guides, from AdComm to Type A meeting.